Zoledronic acid and bone health in older adults with cognitive impairment
- 02.08.2021
- Short Communication
Erschienen in:
- Verfasst von
- B.M. Churilla
- S. Perera
- S.L. Greenspan
- N.M. Resnick
- M.P. Kotlarczyk
- Erschienen in
- Osteoporosis International | Ausgabe 1/2022
Abstract
Summary
Fracture prevention in cognitively impaired individuals is lacking. This work highlights the benefits of zoledronic acid on bone health in cognitively impaired older adults. Demonstrating benefits of therapy may increase treatment uptake and reduce fracture risk in this group.
Introduction
Osteoporosis has detrimental consequences for frail older adults. The effects on those with both osteoporosis and cognitive impairment are compounded due to increased risk of falls and changes in mobility, both of which can lead to fracture. However, there are limited data on treatment benefits for osteoporotic individuals with cognitive impairment.
Methods
This post hoc, secondary analysis of data from a randomized, double-blind, placebo-controlled clinical trial of single-dose zoledronic acid included 179 women age ≥ 65 years residing in assisted living facilities or nursing homes, 43 of whom had mild to severe cognitive impairment. We assessed bone mineral density (BMD) of the total hip, femoral neck, and lumbar spine by dual-energy x-ray absorptiometry and serum bone turnover markers (C-terminal telopeptide of type I collagen and procollagen type I N propeptide) at 6 and 12 months.
Results
In participants with cognitive impairment, those who received zoledronic acid had 4.3% greater BMD at the total hip (p=.005) and 5.3% greater BMD at the femoral neck (p<.001) after 12 months compared to those in the placebo group. Bone turnover markers demonstrated significant decreases at 6 months in those with cognitive impairment who received active treatment compared to the placebo group. Improvements in bone health measures with zoledronic acid were similar to those seen in participants without cognitive impairment.
Conclusion
Zoledronic acid improves bone health in frail older women with cognitive impairment similar to those without impairment. Further studies are warranted to assess the benefit for fracture reduction in this undertreated population.
Anzeige
- Titel
- Zoledronic acid and bone health in older adults with cognitive impairment
- Verfasst von
-
B.M. Churilla
S. Perera
S.L. Greenspan
N.M. Resnick
M.P. Kotlarczyk
- Publikationsdatum
- 02.08.2021
- Verlag
- Springer London
- Erschienen in
-
Osteoporosis International / Ausgabe 1/2022
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965 - DOI
- https://doi.org/10.1007/s00198-021-06063-6
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
